NUZ -- New Investor thread, page-19

Evening all -

Today’s TGA decision to not register LEQEMBI for AD underscores just how difficult it is to take ND drugs through to approval and what a unicorn we’re riding here with NUZ-001.

https://www.tga.gov.au/news/news/tgas-decision-not-register-lecanemab-leqembi

For any new or potential investors, the tremendous safety profile our drug has exhibited is our trump card - it’s a small molecule drug that is uncomplicated when compared to biologics and gene therapies and has - so far - shown itself to be almost benign in regard to adverse events and off target activity at therapeutic doses over extended treatment periods. Unlike many other drug candidates, it’s looking like there will be no reason not to take it.

This is a major point of difference and competitive advantage when compared to most other ND treatments - for some of which the side effects are reported by patients as being almost as bad as the disease being treated.

With circa 2 years of treatment through the MEND study and ongoing OLE showing outstanding safety, tolerability and strong signals of efficacy, NUZ-001 is looking more and more like the biggest step forward in ND treatment ever seen.

Buckle in people.

Cheers

Densy